Edesa Biotech Inc (NASDAQ: EDSA) released findings from an in vitro study involving its monoclonal antibody candidate, paridiprubart. The study, conducted by the University of Toronto, ran parallel to Edesa's ongoing clinical study of EB05 (paridiprubart) in hospitalized Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS), a severe form of respiratory failure characterized by extensive inflammatory damage to the lungs. The preprint research results revealed demonstrate that various